Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01929876 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants

A Phase 1 study, sponsored by Genentech.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT01929876 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01929876, a Phase 1 study, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

This open-label, 2-period, fixed sequence, drug interaction study will investigate the effect of co-administration of itraconazole on the pharmacokinetics of cobimetinib in healthy participants. Participants will receive multiple repeating doses of cobimetinib and itraconazole.

Interventions

  • DRUG Itraconazole
  • DRUG Cobimetinib

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2013-07
Est. Completion 2013-10
Phase Phase 1

Sponsor

Genentech

332 total trials

What the Registry Record Tells You About NCT01929876

The ClinicalTrials.gov registry entry for NCT01929876 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.

NCT01929876 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01929876 about?

NCT01929876 is a clinical study titled "A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants". This open-label, 2-period, fixed sequence, drug interaction study will investigate the effect of co-administration of itraconazole on the pharmacokinetics of cobimetinib in healthy participants. Participants will receive multiple repeating doses of cobimetinib and itraconazole.

What is the current status of trial NCT01929876?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-07. Estimated completion is 2013-10.

What interventions are being tested in trial NCT01929876?

The interventions under investigation include: Itraconazole (DRUG), Cobimetinib (DRUG).

Who is sponsoring clinical trial NCT01929876?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.